Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study

2015; Elsevier BV; Volume: 137; Issue: 3 Linguagem: Inglês

10.1016/j.ygyno.2015.03.042

ISSN

1095-6859

Autores

Robert L. Coleman, Michael W. Sill, Katherine M. Bell‐McGuinn, Carol Aghajanian, Heidi J. Gray, Krishnansu S. Tewari, Stephen C. Rubin, Thomas Rutherford, John K. Chan, Alice Chen, Elizabeth M. Swisher,

Tópico(s)

Ovarian cancer diagnosis and treatment

Referência(s)